Multimer for immunostimulation
View Patent ↗The invention relates to a multimeric non-coding nucleic acid molecule for modulating the activity of the human or animal immune system, and to a preparation process therefore and a vaccine which comprises the multimeric non-coding nucleic acid molecule.
1. A multimeric molecule for modulating the activity of the human or animal immune system, comprising:
at least two covalently closed stem-loop monomer structures,
at least one G structures,
wherein the molecule comprises the base sequence N 1 N 2 CGN 3 N 4 wherein N 1 N 2 is an element from the group of GT, GG, GA, AT or AA, N 3 N 4 is an element from the group of CT or TT, and C is deoxycytosine, G is deoxyguanosine, A is deoxyadenosine, and T is deoxythymidine.
2. The molecule according to claim 1 , comprising the following sequences:
a) GTTCCTGGAG ACGTTCTTAG GAACGTTCTC CTTGACGTTG GAGAGAAC (SEQ ID NO: 1), or
b) ACCTTCCTTG TACTAACGTT GCCTCAAGGA AGGTTGATCT TCATAACGTT GCCTAGATCA (SEQ ID NO: 2), or
c) an oligodeoxyribonucleic acid sequence having the base sequence AACG TTCTTCGGGG CGTT (SEQ ID NO: 3),
wherein said sequence has a length of 40 to 1,600 nucleotides.
3. The molecule according to claim 1 , wherein the base sequence according to feature c) is included in the sequence CCTAGGGGTT ACCACCTTCA TTGGAAAACG TTCTTCGGGG CGTTCTTAGG TGGTAACC CCTAGGGGTT ACCACCTTCA TTGGAAAACG TTCTTCGGGG CGTTCTTAGG TGGTAACC (SEQ ID NO: 4).
4. The molecule according to claim 1 , comprising a partially single-stranded, covalently closed chain of deoxyribonucleoside residues.
5. The molecule according to claim 1 , wherein the base sequence N 1 N 2 CGN 3 N 4 is situated in the single-stranded region of the closed chain of deoxyribonucleoside residues.
6. The molecule according to claim 1 , wherein one or more substituents are linked to the molecule via covalent bonds.
7. The molecule according to claim 6 , wherein the substituent is selected from the group consisting of peptides, proteins, saccharides, antigenic structures, DNA and/or RNA.
8. A kit comprising the molecule according to claim 1 and optionally information relating to combining the contents of the kit.
9. A pharmaceutical agent comprising a molecule according to claim 1 , optionally together with a pharmaceutically tolerable carrier.